Revolution Medicines (RVMD) dropped about 17% after a WSJ report said Merck is no longer discussing an acquisition. There were rumors of a deal worth tens of billions, but they seemingly couldn't agree on a price. Sources noted talks could resume in the future, but they are stalled for now. AbbVie also denied interest earlier this month. The company's lead cancer drug is currently in Phase 3 trials.